Sam Amin, MD

Sam Amin, MD, discusses how phase 3 findings may influence CDD treatment approaches, while emphasizing the need for long-term safety and efficacy data to better define fenfluramine’s role in clinical practice.

Epileptologist Sam Amin, MD, reviews the safety and tolerability findings from the phase 3 fenfluramine study in CDKL5 deficiency disorder, including treatment-emergent adverse events and the absence of major cardiovascular complications.

Sam Amin, MD, reviews the primary and secondary efficacy findings from the phase 3 fenfluramine study in CDKL5 deficiency disorder, highlighting meaningful reductions in seizure burden and improvements in global functioning measures.

Sam Amin, MD, reviews the design of the recent phase 3 fenfluramine study in CDKL5 deficiency disorder, highlighting patient eligibility, baseline seizure burden, concomitant medication use, and key efficacy endpoints.

The discussion opens with a clinical overview of CDKL5 deficiency disorder, focusing on the severe seizure burden, associated developmental complications, and the ongoing limitations of current antiseizure treatment strategies.